.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Advancing Care in Endometrial Cancer: Exploring Long-Term Outcomes and Real-World Evidence

This discussion outlines a panel discussion on advances in advanced/recurrent endometrial cancer, emphasizing how long-term trial outcomes and real-world evidence are reshaping treatment selection, sequencing, toxicity management, and future priorities across molecular subgroups.

EP. 1: Endometrial Cancer Today: Defining the Persistent Unmet Needs in Advanced and Recurrent Disease

December 5th 2025

Panelists discuss how advanced/recurrent endometrial cancer has remained a high unmet need due to years of minimal survival gains with carboplatin/paclitaxel until immunotherapy began shifting outcomes.

EP. 2: Endometrial Cancer: Interpreting dMMR and Post-Adjuvant Activity from LEAP-001

December 5th 2025

Panelists discuss how LEAP-001, despite missing primary endpoints, suggested meaningful activity for lenvatinib plus pembrolizumab in dMMR and post-adjuvant subgroups who may need alternatives to standard frontline chemotherapy.